Vaccinex, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

OTC.Pink

15 Apr 2025

VCNX

10-K: Vaccinex Files 10-K: Focus on Alzheimer's, Strategic Collaborations Highlighted

Vaccinex's 10-K filing reveals a clinical-stage biotech company prioritizing Alzheimer's disease treatment while navigating financial challenges and strategic partnerships.

OTC.Pink

25 Apr 2024

VCNX

Vaccinex, INC

10-K/A: Vaccinex Amends 2023 Annual Report, Cites Audit Signature Omission

Vaccinex, Inc. files an amendment to its 2023 annual report to include the conformed signature of its independent auditor, Deloitte & Touche LLP, which was inadvertently omitted from the original filing.

OTC.Pink

2 Apr 2024

VCNX

Vaccinex, INC

10-K: Vaccinex Inc. Files 10-K Report, Details Clinical Pipeline and Financials

Vaccinex Inc.'s 10-K filing outlines its clinical-stage biopharmaceutical activities, focusing on pepinemab development for neurodegenerative diseases and cancer, alongside financial results and future strategies.